Pancreatic Cancer Research

ResearcherUniversity of GroningenActive in the last 2 years

Marco J. Bruno

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9181-5499; OpenAlex author ID A5042869763. Sources: ClinicalTrials.gov.

Their work

Papers
60 (first author 2, last author 19)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
162
Papers, trials and grants by year

2011: 1 paper, 1 trial · 2012: 4 papers · 2013: 2 papers · 2014: 3 papers · 2015: none · 2016: 3 papers · 2017: 4 papers · 2018: 3 papers · 2019: 3 papers · 2020: 8 papers · 2021: 4 papers · 2022: 10 papers · 2023: 8 papers · 2024: 3 papers · 2025: 2 papers · 2026: 2 papers

Papers 50 of 60

  1. Healthcare expenditures across the care continuum of pancreatic cancer and resected precursor lesions. Co-author DOI 10.1016/j.pan.2026.10.005↗
  2. Real-world implementation of a decision aid for treatment decisions in metastatic pancreatic cancer: a prospective multicenter study across expert centers. Co-author DOI 10.1093/oncolo/oyag373↗
  3. 10-year survival after resection of pancreatic ductal adenocarcinoma with pathological re-examination of a nationwide cohort. Co-author DOI 10.1016/j.ejca.2025.116099↗
  4. Cyst-X: AI-Powered Pancreatic Cancer Risk Prediction from Multicenter MRI in Centralized and Federated Learning Co-author DOI 10.21203/rs.3.rs-7236860/v1↗
  5. Selection of individuals who may benefit from pancreatic cancer surveillance. Co-author DOI 10.1002/ueg2.12660↗
  6. Pancreatic cancer surveillance: Risk stratification of individuals with a germline CDKN2A pathogenic variant. Co-author DOI 10.1002/ueg2.12662↗
  7. Assessment of Glucose and HbA1c Monitoring in a Pancreatic Cancer Surveillance Program for High-Risk Individuals. Co-author DOI 10.14309/ctg.0000000000000777↗
  8. Serum levels of iCAF-derived osteoglycin predict favorable outcome in pancreatic cancer. Co-author DOI 10.1002/ijc.34276↗
  9. The impact of pancreatic cancer screening on life expectancy: A systematic review of modeling studies. Co-author DOI 10.1002/ijc.34379↗
  10. Population-based impact of COVID-19 on incidence, treatment, and survival of patients with pancreatic cancer. Co-author DOI 10.1016/j.hpb.2023.04.017↗
  11. Diagnostic performance of endoscopic tissue acquisition for pancreatic ductal adenocarcinoma in the PREOPANC and PREOPANC-2 trials. Co-author DOI 10.1016/j.hpb.2023.04.018↗
  12. Nationwide evaluation of pancreatic cancer networks ten years after the centralization of pancreatic surgery. Co-author DOI 10.1016/j.hpb.2023.07.904↗
  13. An 8q24 Gain in Pancreatic Juice Is a Candidate Biomarker for the Detection of Pancreatic Cancer. Last author DOI 10.3390/ijms24065097↗
  14. Mutation Analysis of Pancreatic Juice and Plasma for the Detection of Pancreatic Cancer. Last author DOI 10.3390/ijms241713116↗
  15. [Nationwide multidisciplinary developments in pancreatic cancer care in the Netherlands]. Co-author PMID 37994711↗
  16. Hereditary pancreatic cancer. Co-author DOI 10.1016/j.bpg.2021.101783↗
  17. Protein biomarkers in pancreatic juice and serum for identification of pancreatic cancer. Co-author DOI 10.1016/j.gie.2022.04.1342↗
  18. Longitudinal changes of serum protein N-Glycan levels for earlier detection of pancreatic cancer in high-risk individuals. Co-author DOI 10.1016/j.pan.2022.03.021↗
  19. Extracellular vesicle-derived microRNAs in pancreatic juice as biomarkers for detection of pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.pan.2022.04.010↗
  20. Systematic review and meta-analysis: Diagnostic performance of DNA alterations in pancreatic juice for the detection of pancreatic cancer. Co-author DOI 10.1016/j.pan.2022.06.260↗
  21. Timeline of Development of Pancreatic Cancer and Implications for Successful Early Detection in High-Risk Individuals. Last author DOI 10.1053/j.gastro.2021.10.014↗
  22. Long-term yield of pancreatic cancer surveillance in high-risk individuals. Last author DOI 10.1136/gutjnl-2020-323611↗
  23. Three Distinct Stroma Types in Human Pancreatic Cancer Identified by Image Analysis of Fibroblast Subpopulations and Collagen-Letter. Co-author DOI 10.1158/1078-0432.ccr-21-2257↗
  24. Size and Concentration of Extracellular Vesicles in Pancreatic Juice From Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.14309/ctg.0000000000000465↗
  25. Comparing Survival after Resection of Pancreatic Cancer with and without Pancreatic Cysts: Nationwide Registry-Based Study. Co-author DOI 10.3390/cancers14174228↗
  26. Identifying key factors for the effectiveness of pancreatic cancer screening: A model-based analysis. Co-author DOI 10.1002/ijc.33540↗
  27. Genotype-phenotype correlations for pancreatic cancer risk in Dutch melanoma families with pathogenic CDKN2A variants. Co-author DOI 10.1136/jmedgenet-2019-106562↗
  28. Neoantigen Quantity and Quality in Relation to Pancreatic Cancer Survival. Last author DOI 10.3389/fmed.2021.751110↗
  29. Cancer Cell B7-H3 Expression Is More Prevalent in the Pancreato-Biliary Subtype of Ampullary Cancer Than in Pancreatic Cancer. Co-author DOI 10.3389/fonc.2021.615691↗
  30. Patient-reported burden of intensified surveillance and surgery in high-risk individuals under pancreatic cancer surveillance. Last author DOI 10.1007/s10689-020-00171-8↗
  31. Upregulated β-catenin signaling does not affect survival of pancreatic cancer cells during dual inhibition of GSK3B and HDAC. Co-author DOI 10.1016/j.pan.2019.12.019↗
  32. Nationwide compliance with a multidisciplinary guideline on pancreatic cancer during 6-year follow-up. Co-author DOI 10.1016/j.pan.2020.10.032↗
  33. Establishing and Coordinating a Nationwide Multidisciplinary Study Group: Lessons Learned by the Dutch Pancreatic Cancer Group. Co-author DOI 10.1097/sla.0000000000003779↗
  34. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAP… Last author DOI 10.1136/gutjnl-2019-319352↗
  35. Correction: Management of patients with increased risk for familial pancreatic cancer: updated recommendations for the international cancer of the pancreas scr… Co-author DOI 10.1136/gutjnl-2019-319352corr1↗
  36. Prophylactic total pancreatectomy in individuals at high risk of pancreatic ductal adenocarcinoma (PROPAN): systematic review and shared decision-making progra… Co-author DOI 10.1177/2050640620945534↗
  37. Optimization of Pancreatic Juice Collection: A First Step Toward Biomarker Discovery and Early Detection of Pancreatic Cancer. Last author DOI 10.14309/ajg.0000000000000939↗
  38. Surveillance for pancreatic cancer in high-risk individuals. Last author DOI 10.1002/bjs5.50180↗
  39. Pancreatic cancer screening — is it prime time yet? Co-author DOI 10.1038/s41575-019-0221-z↗
  40. Cost-effectiveness of Pancreatic Cancer Surveillance in High-Risk Individuals: An Economic Analysis. Co-author DOI 10.1097/mpa.0000000000001268↗
  41. Pancreatic cancer screening in high-risk individuals: Ready for prime time? Co-author DOI 10.1016/j.gie.2018.02.011↗
  42. Evolution of features of chronic pancreatitis during endoscopic ultrasound-based surveillance of individuals at high risk for pancreatic cancer. Last author DOI 10.1055/a-0574-2396↗
  43. Results of surveillance in individuals at high-risk of pancreatic cancer: A systematic review and meta-analysis. First author DOI 10.1177/2050640617752182↗
  44. Factors associated with cancer worries in individuals participating in annual pancreatic cancer surveillance. Co-author DOI 10.1007/s10689-016-9930-4↗
  45. 3rd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of pancreatic cancer. Co-author DOI 10.1016/j.ejca.2017.03.022↗
  46. Nationwide prospective audit of pancreatic surgery: design, accuracy, and outcomes of the Dutch Pancreatic Cancer Audit. Co-author DOI 10.1016/j.hpb.2017.06.010↗
  47. Prevalence and Progression of Pancreatic Cystic Precursor Lesions Differ Between Groups at High Risk of Developing Pancreatic Cancer. Last author DOI 10.1097/mpa.0000000000000725↗
  48. Repeated participation in pancreatic cancer surveillance by high-risk individuals imposes low psychological burden. Co-author DOI 10.1002/pon.4047↗
  49. A multicentre comparative prospective blinded analysis of EUS and MRI for screening of pancreatic cancer in high-risk individuals. Last author DOI 10.1136/gutjnl-2014-308008↗
  50. Metal or plastic stents for preoperative biliary drainage in resectable pancreatic cancer. Co-author DOI 10.1136/gutjnl-2014-308762↗

Trials 1

  1. Pancreatic Enzyme Suppletion in Pancreatic Cancer Principal investigator NCT01401387↗

Closest collaborators

The 25 strongest of 162 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Djuna L. Cahen · 22 shared papers, 2014–2026 · strength 3.24
  2. Iris J. M. Levink · 13 shared papers, 2020–2024 · strength 2.01
  3. Gwenny Manel Fuhler · 12 shared papers, 2020–2024 · strength 1.93
  4. Marc G. Besselink · 15 shared papers, 2016–2026 · strength 1.87
  5. Jeanin Elise van Hooft · 19 shared papers, 2011–2026 · strength 1.70
  6. Bas Groot Koerkamp · 11 shared papers, 2017–2026 · strength 1.39
  7. Maikel Petrus Peppelenbosch · 11 shared papers, 2012–2023 · strength 1.37
  8. Bert A. Bonsing · 10 shared papers, 2017–2025 · strength 1.26
  9. Casper H.J. van Eijck · 13 shared papers, 2014–2026 · strength 1.23
  10. Ignace H. J. T. de Hingh · 9 shared papers, 2016–2026 · strength 1.09
  11. Brechtje D.M. Koopmann · 7 shared papers, 2021–2024 · strength 1.07
  12. Izaak Quintus Molenaar · 8 shared papers, 2016–2026 · strength 0.86
  13. Femme Harinck · 14 shared papers, 2011–2022 · strength 0.84
  14. Johanna W. Wilmink · 6 shared papers, 2020–2026 · strength 0.82
  15. Ingrid C. A. W. Konings · 10 shared papers, 2016–2022 · strength 0.81
  16. Judith de Vos‐Geelen · 5 shared papers, 2020–2026 · strength 0.77
  17. Kasper A. Overbeek · 7 shared papers, 2020–2022 · strength 0.71
  18. Michail Doukas · 4 shared papers, 2022–2025 · strength 0.63
  19. Marjolein Y.V. Homs · 4 shared papers, 2020–2026 · strength 0.62
  20. Inge M.C.M. de Kok · 3 shared papers, 2021–2026 · strength 0.62
  21. Monique Esther van Leerdam · 4 shared papers, 2013–2024 · strength 0.61
  22. Lydia G. van der Geest · 4 shared papers, 2020–2026 · strength 0.61
  23. Kateryna Nesteruk · 4 shared papers, 2020–2022 · strength 0.59
  24. Derk C.F. Klatte · 3 shared papers, 2022–2024 · strength 0.58
  25. Hjalmar C. van Santvoort · 5 shared papers, 2017–2026 · strength 0.57

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.